SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ACTU

Actuate Therapeutics, Inc. (NASDAQ:ACTU)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.23+$0.01 (+5.38%)
 
Market cap
$5.41M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 13, 2024
Market Cap$5.41M-96.4%
Revenue (ttm)$0
Net Income-$18.47M+23.4%
EPS-$0.78+46.9%
Shares Out24.01M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume629,804
Open$0.20
Previous Close$0.21
Day's Range$0.20 - $0.25
52-Week Range$0.17 - $7.90
Beta0.78
AnalystsBuy
Price Target$21.00(+9220.91%)
Earnings DateMar 25, 2027
+2.90% (1D)
No price history available.

About ACTU

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Address
1751 River Run, Fort Worth, TX, 76107, US
Market Cap
5 million
Employees
12
Industrial Classification
Biotechnology

Actuate Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
52nd Percentile Overall Score
ACTU InsiderScore:70 / 99

Actuate Therapeutics, Inc. scored higher than 52% of companies evaluated by InsiderBuying, and ranked 35th out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Actuate Therapeutics, Inc. bought $50.0K of stock across 1 purchase in the last 90 days, the largest of them $50.0K.

Stake Increase

The average purchase added about 47% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$50.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From ACTU’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars

Next catalysts

1 Day
+5.38%
5 Days
-21.74%
1 Month
-59.93%
6 Months
-90.69%
1 Year
-96.43%

$ACTU stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ACTU holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ACTU's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ACTU Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ACTU patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ACTU from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ACTU

VTIVanguard Morningstar Total Stock Market ETF$75.89K
VXFVanguard Extended Market ETF$35.54K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$10.00K
IWCiShares Micro-Cap ETF$7.42K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ACTU’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
65.39
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
1
Buy Value
$50.00K
Distinct Buyers
1

Insider Score Trend Over Time

-16.0 since Oct 29
0255075100Oct 29 — Insider Score 81.4Oct 30 — Insider Score 80.5Oct 31 — Insider Score 80.4Nov 1 — Insider Score 80.4Nov 2 — Insider Score 80.3Nov 3 — Insider Score 79.8Nov 4 — Insider Score 79.3Nov 5 — Insider Score 78.3Nov 6 — Insider Score 77.5Nov 7 — Insider Score 77.0Nov 8 — Insider Score 77.6Nov 9 — Insider Score 77.6Nov 10 — Insider Score 76.3Nov 11 — Insider Score 75.5Nov 12 — Insider Score 75.2Nov 13 — Insider Score 73.9Nov 14 — Insider Score 72.6Nov 15 — Insider Score 73.2Nov 16 — Insider Score 72.7Nov 17 — Insider Score 70.0Nov 18 — Insider Score 68.6Nov 19 — Insider Score 67.2Nov 20 — Insider Score 66.3Nov 21 — Insider Score 65.4Oct 29Nov 9Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.01%

Weight is the stock’s share of each fund’s holdings.